Nervous Disorder TRIZ Cases

Antibody penetrates blood-brain barrier via FcRn receptor interaction to treat cognitive impairment.

Three-dimensional nerve spheroids enable unidirectional synaptic communication to screen analgesics while maintaining physiological relevance.

MuSK agonist antibodies bypass agrin-LRP4 signaling to cluster receptors and stabilize synapses, addressing limited ALS treatment effectiveness.

Endothelial-specific promoters drive GLUT1 expression in vascular cells, restoring brain glucose availability without dietary restrictions.

Selective LTA4H inhibition reduces neuroinflammation by blocking leukotriene B4 production, addressing the failure of broad anti-inflammatory therapies.

Chewing gum formulation uses specific 50 to 2000 µm particle sizes to enable rapid cannabinoid absorption without combustion risks.

Synthetic RgIA analogs use penicillamine substitution to block alpha9alpha10 nAChR receptors for targeted analgesia.

Administering PAN-811 thiosemicarbazone mitigates chemotherapy-induced cognitive deficits by reducing oxidative stress in the central nervous system.

IL-22 dimer activates STAT3 signaling to protect dopaminergic neurons, addressing neurodegenerative disease progression.

Using (+)-α-dihydrotetrabenazine to treat movement disorders while avoiding dose-related depression and parkinsonism.

Preconditioning with a serotonin 5-HT1A agonist allows lower dopamine doses, reducing dyskinesia while controlling rigidity.

Humanized antibodies bind amyloid beta proteins to inhibit aggregation and induce disaggregation of preformed fibrils.

A fusion peptide derivative combines a cell-penetrating sequence with an endosomal-escape portion to traverse biological barriers.

Ultra-micronized palmitoylethanolamide uses fluid jet micronization to produce particles under 6 microns.

Pyridine-based compounds activate Kv7 channels, improving therapeutic efficacy while reducing side effects in epilepsy treatment.

Vascular apotransferrin administration protects brain tissue by sequestering iron to prevent oxidative stress and inflammatory damage during reperfusion.

PEG hydrogel bound capture peptides trap beta-amyloid in peripheral circulation, preventing blood-brain barrier crossing and reducing brain plaque formation.

Uridine and DHA composition supports brain development.

A cytokine and receptor peptide composition alters immune system functioning by binding to specific chemokines.

Targeted amino acid mutations in CDR regions reduce immunogenicity while preserving binding activity, treating central nervous system damage.

IL-1alpha markers enable selective targeting of CD14+CD16+ monocytes, avoiding generalized immunosuppression from broad leukocyte depletion.

CDR grafting transfers complementarity determining regions into stable antibody frameworks to preserve antigen binding affinity.

A bispecific molecule uses APRIL to bind BCMA and recruit T cells, forming trimers that amplify immune signals.

Humanized antibodies bind pyroglutamated amyloid beta N3pE peptides, clearing neurotoxic aggregates that conventional therapies fail to address.

Segment patients by retromer dysfunction status to apply specific stabilization therapies, resolving low efficacy in general neurodegenerative treatments.

Modifying RNA-binding protein sequences with proline residues prevents aggregation while retaining essential cellular functions.

Pluripotent Muse cell preparations reduce infarct size and restore brain function by differentiating into nerve cells within damaged cerebral parenchyma.

Formula I binds the CRY1 FAD pocket to enhance degradation, correcting rhythm disorders without toxic side effects.

Targeting pathogenic microglial clones with MAPK inhibitors enables personalized treatment strategies for neurodegenerative conditions.

Developed monoclonal antibodies target human DEC-205 receptors on dendritic cells, resolving the trade-off between targeting accuracy and reagent availability.

Culturing pluripotent stem cells with ALK and GSK-3β inhibitors to generate neural crest cells specialized for mesenchymal lineage differentiation.

Segmenting receptor targeting via N-alkylation reduces off-target side effects while maintaining therapeutic efficacy.

Administering purified microbiota alters gut composition to promote weight loss.

Optimized fully human antibodies bind PD-1 epitopes with high affinity, resolving insufficient binding specificity in cancer treatments.

Chromatographic profiling establishes quantitative standards for traditional medicines, resolving reproducibility issues in complex herbal formulations.

A single-chain fusion polypeptide uses peptide linkers to connect three soluble TNF superfamily cytokine domains.

Monoclonal antibodies bind phosphorylated serine 396 on tau proteins to selectively deplete pathological aggregates in the retina.

Lactobacillus reuteri and Bifidobacterium animalis subsp. lactis compositions modify gut microbiome composition to improve body mass index.

IL-1 binding proteins neutralize IL-1α and IL-1β cytokines, blocking inflammatory pathways that drive osteoarthritis progression.

PK-4 peptides sequester circulating beta-amyloids via high-affinity binding, preventing blood-brain barrier entry and reducing cognitive decline.

Oral GMGB1 supplements replace invasive monoclonal antibody injections to reduce TNF, IL-1, and IL-6 levels while eliminating injection-related adverse effects.

A single IFN-beta fused to a mutated IgG Fc fragment extends serum half-life while reducing ADCC and CDC side effects.

Multi-enzyme formulation breaks down histamine in the gut, resolving trade-offs between strict dietary restrictions and patient compliance.

Segmented antibody screening detects GABAB receptor markers to resolve diagnostic accuracy trade-offs in autoimmune encephalitis cases.

VHH antibody conjugates cross the blood-brain barrier to image amyloid plaques, replacing radioactive PET tracers with safer magnetic resonance detection.

Camelid VHH antibody fragments traverse the blood-brain barrier and cell membranes to detect intracellular glial fibrillary acidic protein.

Arachidonic acid composition overcomes ineffective conventional drug therapies to improve depressive symptoms.

Guanabenz regulates eIF2B activity via eIF2 phosphorylation, slowing disease progression and reducing deterioration episodes in vanishing white matter.

Microprotein scaffolds stabilize polypeptides against proteolytic degradation, extending plasma half-life while maintaining receptor affinity.